Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Etypharm
PolandAll drugs from this manufacturer
-
The medicine is intended for the treatment of breakthrough pain in adult cancer patients who are already using other analgesics to manage chronic cancer pain. Breakthrough pain is sudden, additional pain that occurs despite regular intake of opioid medications.
Dosage form: tablets, sublingual
Active substance Dosage fentanyl citrate 0.11 mg ATC: N02AB03
-
The medicine is used in adult patients with cancer to treat breakthrough pain. This is sudden, additional pain that occurs despite regular intake of other analgesics used for chronic pain.
Dosage form: tablets, sublingual
Active substance Dosage fentanyl citrate 0.21 mg ATC: N02AB03
-
The medicine is intended for the treatment of breakthrough pain in adult cancer patients who are already using other analgesics to manage chronic pain.
Dosage form: tablets, sublingual
Active substance Dosage fentanyl citrate 0.84 mg ATC: N02AB03